05:17 PM EDT, 06/03/2024 (MT Newswires) -- Legend Biotech ( LEGN ) said late Monday data from the phase 2 CARTITUDE-2 cohort D study in people with multiple myeloma showed that patients with a less-than-complete response after autologous stem cell transplant had "deep and durable responses" after a single infusion of Carvykti.

"We are conducting phase 3 studies to determine if patients will benefit from Carvykti as early as frontline treatment," Legend Chief Medical Officer Mythili Koneru said.

Results of a subgroup analysis of the CARTITUDE-4 phase 3 trial assessing Carvykti versus two standard of care treatments in people with multiple myeloma showed Carvykti "significantly improved" progression free survival for people with functional high-risk multiple myeloma, the company said.

Legend also said data from the phase 3 CARTITUDE-4 subgroup analysis showed the efficacy of Carvykti versus standard of care treatments in people with high-risk-cytogenetics.

Legend has a license and collaboration deal with Johnson & Johnson ( JNJ ) unit Janssen Biotech to develop and commercialize Carvykti.